Valneva (VALN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Valneva (VALN) is a FR-listed Healthcare company in Biotechnology with a market capitalization of $468M, trading at $4.94 on the NASDAQ. This SniperIQ fundamentals page covers Valneva's valuation, profitability (net margin -88.3%), revenue (€175M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Valneva's market cap?
Valneva (VALN) has a market capitalization of approximately $468M, trading at $4.94 on the NASDAQ. Market cap moves with the live share price.
What is Valneva's P/E ratio?
Valneva's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Valneva?
Valneva runs a net profit margin of -88.3%, a gross margin of 29.5%, and an operating margin of -68.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Valneva generate?
Valneva reported revenue of €175M for fiscal year 2025, with net income of -€115M and earnings per share (EPS) of -1.32. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Valneva pay a dividend?
Valneva does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Valneva financially healthy?
Valneva carries a debt-to-equity ratio of 2.73x and a current ratio of 2.14x, with a market beta of 1.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Valneva a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Valneva (VALN) the key facts are: market cap $468M, revenue €175M, 52-week range 4.84-12.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Valneva's full fundamentals live
Get Valneva's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.